Marta Tonello

Dr. Marta Tonello

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
CNCecilia Nalli
Cecilia Nalli
DLDaniele Lini
Daniele Lini
LALaura ANDREOLI
Laura ANDREOLI
FCFrancesca Crisafulli
Francesca Crisafulli
MFMicaela Fredi
Micaela Fredi
ATAngela Tincani
Angela Tincani
Antiphospholipid antibodies (aPL) can induce fetal loss in experimental animal models. Human studies did find hypocomplementemia associated with pregnancy complications in patients with antiphospholipid syndrome (APS), but these results are not unanimously confirmed. To investigate if the detection of low C3/C4 could be considered a risk factor for adverse pregnancy outcomes (APO) in APS and aPL carriers’ pregnancies we performed a multicenter study including 503 pregnancies from 11 Italian and 1 Russian centers. Data in women with APS and asymptomatic carriers with persistently positive aPL and preconception complement levels were available for 260 pregnancies. In pregnancies with low preconception C3/C4, a significantly higher prevalence of pregnancy losses was observed (p = 0.008). A subgroup analysis focusing on triple aPL-positive patients found that preconception low C3 and/or C4 levels were associated with an increased rate of pregnancy loss (p = 0.05). Our findings confirm that decreased complement levels before pregnancy are associated with increased risk of APO. This has been seen only in women with triple aPL positivity, indeed single or double positivity does not show this trend. Complement levels are cheap and easy to be measured therefore they could represent a useful aid to identify patients at increased risk of pregnancy loss.

1 May 2019 in Thrombosis Research
Verified
Journal Article
Closed access
MTMarta Tonello
Marta Tonello
EMElena Mattia
Elena Mattia
MFMaria Favaro
Maria Favaro
TRTeresa Del Ross
Teresa Del Ross
ACAntonia Calligaro
Antonia Calligaro
ARAmelia Ruffatti
Amelia Ruffatti

24 April 2024 in RMD Open
Verified
Journal Article
Open access
PDF file
LALaura ANDREOLI
Laura ANDREOLI
MGMaria Chiara Gerardi
Maria Chiara Gerardi
MGMaria Gerosa
Maria Gerosa
DRDavide Rozza
Davide Rozza
FCFrancesca Crisafulli
Francesca Crisafulli
ATAngela Tincani
Angela Tincani
Objectives To investigate pregnancy outcomes in women with autoimmune rheumatic diseases (ARD) in the Italian prospective cohort study P-RHEUM.it. Methods Pregnant women with different ARD were enrolled for up to 20 gestational weeks in 29 Rheumatology Centres for 5 years (2018–2023). Maternal and infant information were collected in a web-based database. Results We analysed 866 pregnancies in 851 patients (systemic lupus erythematosus was the most represented disease, 19.6%). Maternal disease flares were observed in 135 (15.6%) pregnancies. 53 (6.1%) pregnancies were induced by assisted reproduction techniques, 61 (7%) ended in miscarriage and 11 (1.3%) underwent elective termination. Obstetrical complications occurred in 261 (30.1%) pregnancies, including 2.3% pre-eclampsia. Two cases of congenital heart block were observed out of 157 pregnancies (1.3%) with anti-Ro/SSA. Regarding treatments, 244 (28.2%) pregnancies were treated with glucocorticoids, 388 (44.8%) with hydroxychloroquine, 85 (9.8%) with conventional synthetic disease-modifying anti-rheumatic drugs and 122 (14.1%) with biological disease-modifying anti-rheumatic drugs. Live births were 794 (91.7%), mostly at term (84.9%); four perinatal deaths (0.5%) occurred. Among 790 newborns, 31 (3.9%) were small-for-gestational-age and 169 (21.4%) had perinatal complications. Exclusive maternal breast feeding was received by 404 (46.7%) neonates. The Edinburgh Postnatal Depression Scale was compiled by 414 women (52.4%); 89 (21.5%) scored positive for emotional distress. Conclusions Multiple factors including preconception counselling and treat-to-target with pregnancy-compatible medications may have contributed to mitigate disease-related risk factors, yielding limited disease flares, good pregnancy outcomes and frequency of complications which were similar to the Italian general obstetric population. Disease-specific issues need to be further addressed to plan preventative measures.

30 March 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
MTMarta Tonello
Marta Tonello
ARAmelia Ruffatti
Amelia Ruffatti
PMPiero Marson
Piero Marson
TTTiziana Tison
Tiziana Tison
LMLuca Marozio
Luca Marozio
LPLeonardo Punzi
Leonardo Punzi

24 March 2016 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
MTMarta Tonello
Marta Tonello
ARAmelia Ruffatti
Amelia Ruffatti
MFMaria Favaro
Maria Favaro
TTTiziana Tison
Tiziana Tison
TRTeresa del Ross
Teresa del Ross
LPLeonardo Punzi
Leonardo Punzi
Objective This prospective study aimed to identify antibody profiles characterising mothers with fetuses developing congenital heart block (CHB) by comparing their antibody frequencies and levels with those in unaffected mothers. Methods Eighty-one consecutive pregnant patients positive to anti-Ro±anti-La antibodies, at high risk of developing fetal CHB were prospectively studied. The 16 patients with fetal CHB outcome were considered the study population and the 65 patients with normal pregnancy outcomes were considered the control cohort. Anti-Ro52, anti-Ro60, anti-p200 and anti-La antibodies were assayed using home-made ELISA assays. Results The prevalence of anti-p200 antibodies was significantly higher in the fetal CHB affected patients than in the controls (p=0.03). Combinations of anti-p200 with anti-Ro52 and anti-Ro60 antibodies were significantly more frequent in the women with fetuses developing CHB than in the controls (p=0.03 for all combinations). The women with fetal CHB had significantly higher mean anti-Ro52, anti-Ro60 and anti-p200 levels than the controls (p=0.003, p=0.0001 and p=0.04, respectively); mean anti-La/SSB level was not significantly different in the two cohorts (p=0.25). Conclusions Since anti-p200, anti-Ro52 and anti-Ro60 antibodies, especially at high level, seem to identify patients at increased risk of developing fetal CHB, their detection could recognise anti-Ro/La positive women at risk for having an infant with this rare, potentially dangerous disorder.

1 October 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
MTMarta Tonello
Marta Tonello
EME. Mattia
E. Mattia
TRT. Del Ross
T. Del Ross
MFM. Favaro
M. Favaro
ACA. Calligaro
A. Calligaro
ARA. Ruffatti
A. Ruffatti